Fumagillin treatment of hepatocellular carcinoma in rats: An in vivo study of antiangiogenesis

World Journal of Gastroenterology

Volumn 11, Issue 6, 2005, Pages 771-777

  Sheen, I Shyan ^a   Jeng, Kuo Shyang ^b   Jeng, Wen Juei ^c   Jeng, Chi Juei ^d   Wang, Yi Ching ^b   Gu, Shu Ling ^b   Tseng, Shin Yun ^b   Chu, Chien Ming ^b   Lin, Chia Hui ^b   Chang, Kuo Ming ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Antiangiogenesis therapy; Fumagillin; Hepatocellular carcinoma; MetAP 2

Indexed keywords

ANGIOGENESIS INHIBITOR; DIETHYLNITROSAMINE; FUMAGILLIN; MESSENGER RNA; METHIONYL AMINOPEPTIDASE; PROTEIN BCL 2; TELOMERASE;

ADULTHOOD; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER TUMOR; LIVER WEIGHT; MALE; METASTASIS; NONHUMAN; RAT; RAT STRAIN; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TUMOR GROWTH;

EID: 20044386113     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i6.771     Document Type: Article

References (38)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-1185
2. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6
3. Denekamp J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993; 66: 181-196
4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31
5. Fox SB, Gatter KC, Harris AL. Tumor angiogenesis. J Pathol 1996; 179: 232-237
6. Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 2000; 60 4066-4069
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364
8. Gleich LL, Zimmerman N, Wang YO, Gluckman JL. Angiogenic inhibition for treatment of head and neck cancer. Anticancer Res 1998; 18: 2607-2610
9. Yanase T, Tamura M, Fulita K, Kodama S, Tanaka K. Inhibitory effect of angiogenesis inhibitor TPN-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 1993; 53: 2566-2570
10. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348: 555-557
11. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, Fujita T. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillin (TNP-470; AGM 1470). Cancer Res 1993; 53: 4262-4267
12. Konno H, Tanaka T, Matsuda I, Kanai T, Maruo Y, Nishino N, Nakamura S, Baba S. Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP-70, and mitomycin C on the growth and liver metastasis of human colon cancer. Int J Cancer 1995; 61: 268-271
13. Tanaka T, Konno H, Matsuda I, Nakamura S, Baba S. Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res 1995; 55: 836-839
14. Wyllie AH. Apoptosis: Cell death in tissue regulation. J Pathol 1987; 153: 313-316
15. Kusaka M, Sudo K, Matsutani E, Kozai Y, Marui S, Fujita T, Ingber D, Folkman J. Cytostatic inhibition of endothelial cell grow by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994; 69: 212-216
16. Abe J, Zhou W, Takuwa N, Taguchi J, Kurokawa K, Kumada M, Takuwa Y. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 1994; 54: 3407-3412
17. Singh Y, Shikata N, Kiyozuka Y, Nambu H, Morimoto J, Kurebayashi J, Hioki K, Tsubura A. Inhibition of tumor growth and metastasis by angiogenesis inhibitor TNP-470 on breast cancer cell lines in vitro and in vivo. Breast Cancer Res Treat 1997; 45: 15-27
18. Castronovo V, Belotti D. TNP-470 (AGM-1470): Mechanisms of action and early clinical development. Eur J Cancer 1996; 32A 2520-2527
19. Isobe N, Uozumi T, Kurisu K, Anbe N, Uozumi T, Kurisu K. TNP-470 on glial tumor transplanted in rats. Anticancer Res 1996; 16: 71-76
20. Kin M, Torimura T, Ueno T, Nakamura T, Ogata R, Sakamoto M, Tamaki S, Sata M. Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats. Int J Oncol 2000; 16: 375-382
21. Zimmerman MA, Selzman CH, Harken AH. Surgical implications of therapeutic angiogenesis. Surgery 1999; 125: 243-249
22. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003; 13: 159-167
23. Prox D, Becker C, Pirie-Shepherd SR, Celik I, Folkman J, Kisker O. Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World J Surg 2003; 27: 405-411
24. Catalano A, Romano M, Robuffo I, Strizzi L, Procopio A. Methionine aminopeptidase-2 regulates human mesothelioma cell survival. Am J Pathol 2001; 159: 721-731
25. Yoshida T, Kaneko Y, Tsukamoto A, Han K, Ichinose M, Kimura S. Suppression of hepatoma growth and angiogenesis by a fumagillin derivative TNP470: possible involvement of nitric oxide synthase. Cancer Res 1998; 58: 3751-3756
26. Klohs WD, Hamby JM. Antiangiogenic agents. Curr Opin Biotechnol 1999; 10: 544-549
27. Bradshaw RA, Yi E. Methionine aminopeptidases and angiogenesis. Essays Biochem 2002; 38: 65-78
28. Sin NY, Meng L, Wang MQW, Wen JJ, Bornmann WG, Crews CM. The ani-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase metAP-2. Proc Natl Acad Sci USA 1997; 94: 6099-6103
29. Wang J, Lou P, Henkin J. Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases. J Cell Biochem 2000; 77: 465-473
30. Iida A, Yamaguchi A, Hirose K. Telomerase activity in colorectal cancer and its relationship to bcl-2 expression. J Surg Oncol 2000; 73: 219-223
31. Kishimoto K, Fujimoto J, Takeuchi M, Yamamoto H, Ueki T, Okamoto E. Telomerase activity in hepatocellular carcinoma and adjacent liver tissues. J Surg Oncol 1998; 69: 119-124
32. Takahashi S, Kitamoto M, Takaishi H, Aikata H, Kawakami Y, Nakanishi T, Shimamoto F, Tahara E, Tahara H, Ide T, Kajiyama G. Expression of telomerase component genes in hepatocellular carcinomas. Eur J Cancer 2000; 36: 496-502
33. Shimada M, Hasegawa H, Gion T, Utsunomiya T, Shirabe K, Takenaka K, Otsuka T, Maehara Y, Sugimachi K. The role of telomerase activity in hepatocellular carcinoma. Am J Gastroenterol 2000; 95: 748-752
34. Elkak AE, Kirkpatrick K, Mears L, Wells C, Ghilchik M, Newbold R, Mokbel K. Telomerase activity and Bcl-2 expression in human breast cancer. Eur J Surg Oncol 2002; 28: 14-18
35. Mandal M, Kumar R. Bcl-2 modulates telomerase activity. J Biol Chem 1997; 272: 14183-14187
36. Ohmura Y, Aoe M, Andou A, Shimizu N. Telomerase activity and Bcl-2 expression in non-small cell lung cancer. Clin Cancer Res 2000; 6: 2980-2987
37. Kenmochi K, Sugihara S, Kojiro M. Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in single small HCC. Liver 1987; 7: 18-26
38. Ohta K, Kanamaru T, Morita Y, Hayashi Y, Ito H, Yamamoto M. Telomerase activity in hepatocellular carcinoma as a predictor of postoperative recurrence. J Gastroenterol 1997; 32 791-796